🟢 Painreform is trading 8.42% up — no confirmed catalyst

Painreform is trading at $0.82, up 8.42%, with no verified company-specific announcement explaining the October 28 move.

• The latest identified company update was October 23, covering cash, a planned Phase 2 trial and an AI data-center opportunity—not a new October 28 catalyst.
• Biotech-sector strength may provide background, but evidence does not establish it as the direct cause; available coverage also reported no confirmed explanation for the earlier premarket decline.